Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 3Observational 1Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Renal Insufficiency 1Osteosarcoma 1Neoplasms 1Lymphoma 1Leukemia 1

Interventions

nilotinib 5venetoclax 3midostaurin 3ponatinib 2navitoclax 2gilteritinib 2fludarabine phosphate 2asparaginase erwinia chrysanthemi recombinant 2tisagenlecleucel 1revumenib 1pirtobrutinib 1magrolimab 1ivosidenib 1immunotoxin HA22 1idelalisib 1ibrutinib 1glucarpidase 1fludarabine 1eryaspase 1enasidenib 1cc-486 1brexucabtagene autoleucel 1asciminib 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Immunotherapy, Adoptive 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × glucarpidase × Other hematologic neoplasm × Clear all
NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡